Apellis Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Crestwood KY United States (2008)

Organization Overview

First Clinical Trial
2014
NCT02264639
First Marketed Drug
2021
pegcetacoplan (Empaveli)
First NDA Approval
2021
pegcetacoplan (Empaveli)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Apellis Pharmaceuticals, Inc. | APELLIS PHARMS

Active Ingredients

Marketed Drugs (1)

pegcetacoplan (Empaveli) (2021 NDA)

Drugs in Phase 3 Trials (2)

eculizumab (Soliris) (1 trial)

pegcetacoplan (Empaveli) (22 trials)

Drugs in Phase 2 Trials (1)

apl-9 (1 trial)

Drugs in Phase 1 Trials (1)

Key: Apellis Pharmaceuticals, Inc. (0) Acquired (1)

compstatin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Anemia (Phase 2)

Anemia, Hemolytic (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Atrophy (Phase 3)

Coronavirus Infections (Phase 2)

Geographic Atrophy (Phase 3)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Glomerulonephritis, Membranoproliferative (Phase 2)

Glomerulonephritis, Membranous (Phase 2)

Hemoglobinuria (Phase 3)

Hemoglobinuria, Paroxysmal (Phase 3)

Hemolysis (Phase 2)

Kidney Diseases (Phase 2)

Lupus Nephritis (Phase 2)

Macular Degeneration (Phase 3)

Motor Neuron Disease (Phase 2)

Nephritis (Phase 2)

Recurrence (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Sclerosis (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Syndrome (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 4